Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Dermatologic 1

Conditions

Clear-cell metastatic renal cell carcinoma 1Carcinoma, Renal Cell 1

Interventions

Magnetic Resonance Spectroscopy 101Specimen Handling 82pembrolizumab 78enzalutamide 63Nivolumab 60Gemcitabine 54Docetaxel 52apalutamide 42Radiosurgery 41Abiraterone Acetate 40Prednisone 39Androgen Antagonists 39Biopsy 37darolutamide 36Cisplatin 35cabozantinib 33Radiotherapy 32Carboplatin 29Pluvicto 28enfortumab vedotin 27abiraterone 27Ipilimumab 25Radiation 23durvalumab 22atezolizumab 22Leuprolide 20olaparib 19X-Rays 19Standard of Care 18avelumab 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
sitravatinib × Genitourinary × 90 days × Clear all
NCT04904302 2026-03-20

Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer

M.D. Anderson Cancer Center

Phase 2 Terminated
15 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡